Want to see HK:6990 full AI Analyst Report?
Total Valuation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has a market cap or net worth of HK$129.18B. The enterprise value is HK$8.76B.
Market CapHK$129.18B
Enterprise ValueHK$8.76B
Share Statistics
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 176,822,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding176,822,250
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -9.09%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.09%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee1.01M
Profits Per Employee-173.98K
Employee Count2,045
Asset Turnover0.34
Inventory Turnover2.40
Valuation Ratios
The current PE Ratio of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is ―. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s PEG ratio is -5.55.
PE Ratio―
PS Ratio39.59
PB Ratio16.74
Price to Fair Value16.74
Price to FCF-265.74
Price to Operating Cash Flow-512.07
PEG Ratio-5.55
Income Statement
In the last 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H had revenue of 2.06B and earned -381.97M in profits. Earnings per share was -1.66.
Revenue2.06B
Gross Profit1.48B
Operating Income-466.19M
Pretax Income-355.78M
Net Income-381.97M
EBITDA-249.23M
Earnings Per Share (EPS)-1.66
Cash Flow
In the last 12 months, operating cash flow was -191.74M and capital expenditures -137.82M, giving a free cash flow of -329.56M billion.
Operating Cash Flow-191.74M
Free Cash Flow-329.56M
Free Cash Flow per Share-1.86
Dividends & Yields
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.70
52-Week Price Change25.17%
50-Day Moving Average444.67
200-Day Moving Average445.36
Relative Strength Index (RSI)61.85
Average Volume (3m)641.47K
Important Dates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H upcoming earnings date is Aug 24, 2026, TBA (Confirmed).
Last Earnings DateMar 23, 2026
Next Earnings DateAug 24, 2026
Ex-Dividend Date―
Financial Position
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H as a current ratio of 5.13, with Debt / Equity ratio of 1.82%
Current Ratio5.13
Quick Ratio4.89
Debt to Market Cap<0.01
Net Debt to EBITDA13.01
Interest Coverage Ratio-75.71
Taxes
In the past 12 months, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has paid 26.19M in taxes.
Income Tax26.19M
Effective Tax Rate-0.07
Enterprise Valuation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H EV to EBITDA ratio is -313.85, with an EV/FCF ratio of -255.16.
EV to Sales38.01
EV to EBITDA-313.85
EV to Free Cash Flow-255.16
EV to Operating Cash Flow-433.83
Balance Sheet
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has HK$4.56B in cash and marketable securities with HK$88.44M in debt, giving a net cash position of HK$4.47B billion.
Cash & Marketable SecuritiesHK$4.56B
Total DebtHK$88.44M
Net CashHK$4.47B
Net Cash Per ShareHK$25.28
Tangible Book Value Per ShareHK$21.11
Margins
Gross margin is 71.88%, with operating margin of -22.65%, and net profit margin of -18.56%.
Gross Margin71.88%
Operating Margin-22.65%
Pretax Margin-17.29%
Net Profit Margin-18.56%
EBITDA Margin-12.11%
EBIT Margin-16.99%
Analyst Forecast
The average price target for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H is HK$561.61, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$561.61
Price Target Upside8.00% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast6.59%
EPS Growth Forecast-46.41%